Case Report

Rh E^w^ antigen in a multi-transfused patient with sickle cell disease

Vitor Mendonça Alves^a^, Paulo Roberto Juliano Martins^a^,b^, Fernanda Bernadelli De Vito^a^, Lilian Castilo^c^, Helio Moraes-Souza^a^,b^,*

^a^ Universidade Federal do Triângulo Mineiro (UFTM), Uberaba, MG, Brazil
^b^ Hemocentro Regional de Uberaba, Fundação HEMOMINAS, Uberaba, MG, Brazil
^c^ Hemocentro da Universidade Estadual de Campinas (UNICAMP), Campinas, SP, Brazil

**A R T I C L E   I N F O**

Article history:
Received 10 December 2017
Accepted 19 February 2018
Available online 23 April 2018

**Introduction**

The Rh blood system is the second in clinical importance in transfusions and gestations; however, it is the most complex with more than 50 antigens already having been described. Of the antigens, D, C, c, E and e, whose alloantibodies react at 37 °C and cause hemolysis, are responsible by the vast majority of intercurrences in transfusions and gestations. The E antigen is expressed by the RHCE gene and differs from the e antigen by a single nucleotide polymorphism (SNP) (676C>G; Pro226Ala).^5^ The E^w^ antigen, a rare variant of the E antigen, was described for the first time in 1955. According to some reports in the literature, it is only found in Caucasians with a frequency of less than 0.1%.^6^ A hemolytic disease of the newborn (HDN) caused by anti-E^w^ maternal antibodies was reported in two of these reports^7^; in another, an anti-E alloantibody was found in an E^w^ positive patient, after receiving E positive red blood cells (RBCs).^8^ Although the antigen has been described only in Caucasians (and at a very low frequency), in this study, we found the phenotype with a molecular basis in a patient of mixed ethnicity (neither White nor Black) and sickle cell disease (SCD), highlighting the high level of miscegenation in Brazil.

**Case report**

We report on the case of a 30-year-old male patient with a RhD+ blood type and SCD and a history of more than 100 packed RBC transfusions at the Hemocentro Regional de Uberaba/Fundação Hemominas. He was of mixed ethnicity (White and Black) as were his ancestors (parents and grandparents). In 2009, his results of RBC alloantibody screening were positive; however, the antibody (present as a low titer) was not identified. In the same year, his erythrocyte phenotyping was performed by the Immunohematology Center of the Fundação Hemominas (Belo Horizonte, Brazil) and defined as Rh [C-c+ (Cw−); E+ (weak positive) e+]; K−; Fy (a+b+); Jk (a+b+); S-s+.

^*^ Corresponding author at: Hemocentro Regional de Uberaba/Fundação Hemominas, Avenida Getúlio Guaritá, 250, Abadia, 38025-440 Uberaba, MG, Brazil.
E-mail address: helio.moraes@uftm.edu.br (H. Moraes-Souza).

https://doi.org/10.1016/j.htct.2018.02.007

2531-1379/© 2018 Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
In 2014, after he gave his consent, a new blood sample was collected, with the RBCs submitted to a repeat phenotyping test using the gel centrifugation technique and the ID-DiaClon Rh-Subgroups+K card (DiaMed-Biorad Latin America, Lagoa Santa, Minas Gerais, Brazil), with monoclonal antibodies, the while the leukocytes had the DNA extracted using the Flexigene kit (Qiagen, Hilden, Germany). In both tests, the manufacturer's recommendations were followed. The DNA was submitted to RBC genotyping by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) and BeadChip wRHCE2.1 (Bioarray Solutions, Immucor, Warren, NJ, USA), also following the manufacturer's recommendations.

PCR was performed with 50–100 ng of DNA, 0.25 μM of each primer, 0.25 mM of each dNTP, 2.5 mM of MgCl₂, 1.0 U Taq DNA polymerase and buffer 1×. PCR amplification was performed in a Veriti™ 96-well Thermal Cycler (Applied Biosystems, Foster City, CA, USA). The following conditions were used: denaturation at 95 °C for 15 min, followed by 35 cycles at 95 °C for 30 s, 62 °C for 30 s and 72 °C for 40 s, and a final extension step of 72 °C for 10 min. Amplified products were analyzed by electrophoresis in 1.5% agarose gel in Tris-Borate EDTA buffer (TBE). For enzyme digestion, the PCR product was incubated with Mnl I restriction enzyme overnight at 37 °C according to the manufacturer’s recommendations. All reagents used in the PCR reactions were obtained from Applied Biosystems, Foster City, CA, USA. The RFLP analysis was performed after electrophoresis in 3.5% agarose gel in TBE. Primer sequences used in the PCR are described in Table 1.

As one result of phenotyping (Rh(E-e+)) and genotyping (RHCE*E/RHCE*e) was discrepant, and he had not received transfusions of red blood cells in the 12 months preceding the last blood collection, his DNA sample was submitted to a sequencing of the RHCE gene, in order to identify the cause of the discrepancy.

All 10 exons of RHCE were sequenced. Amplification was performed with RHCE-specific primers designed to target flanking intronic regions (7) and sequencing analysis was performed in a 3500xL Genetic Analyzer (Applied Biosystems, Foster City, CA, USA). Primer sequences and annealing temperature are described in Table 2.

Table 1 – Primer sequences used in polymerase chain reaction-restriction fragment length polymorphism for RHCE*E/e genotyping.

<table>
<thead>
<tr>
<th>Primer</th>
<th>Primer sequence (5′→3′)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CE4 (sense)</td>
<td>GCACACAGCCAGGGAGTTG</td>
</tr>
<tr>
<td>CEX5 (antisense)</td>
<td>CTGATTTCCCTTTGGGGTG</td>
</tr>
</tbody>
</table>

Discussion

In the present case, although the patient was genotyped as RHCE*E/RHCE*e, his respective phenotype was defined as E+ (weak positive) and E negative in the first and the second phenotyping tests, respectively. This discrepancy was due to the presence of three polymorphisms (361A>T, 380C>T and 383G>A) identified in the RHCE gene sequencing, responsible for the E⁺ antigen. A different molecular basis had already been identified: 500T>A; Met167Lys. As already cited, there is a report of anti-E alloimmunization in a E⁺ positive patient after receiving E positive erythrocytes. It is thus advisable to transfuse only E negative RBCs in these individuals.

Our results clearly reinforce the importance of erythrocyte phenotyping and genotyping as complementary tests in the transfusion routine of multi-transfused patients or candidates for chronic transfusions of RBCs, as in some cases, the detection of a certain allele by one molecular technique does not necessarily mean its complete or partial expression. In these situations, DNA sequencing is paramount, including in other cases where RBC phenotype and genotype discrepancies cannot be solved by molecular methodologies currently used in the routine and the patient has no history of recent transfusions.

Lastly, it is important to highlight the singularity of this case, considering that the phenotype has been detected in about 1:1000 Caucasians, with no reports in other ethnicities; however, here it was identified in a patient with sickle cell disease, which originates from the Black population. As the patient was mixed and reported that his parents and grandparent had the same ethnicity, this shows the high level of miscegenation of the Brazilian population.
Conflicts of interest

The authors declare no conflicts of interest.

Acknowledgements

To Emília Ângela Sippert, PhD, for performing the BeadChip technique and RHCE gene sequencing at the Laboratório de Biologia Molecular de Grupos Sanguíneos da Universidade Estadual de Campinas (UNICAMP).

REFERENCES


Figure 1 – Result of the RHCE gene sequencing, with three polymorphisms compatible with the RHCE*cE.15.02/RHCE*ce genotype.